PARDES BIOSCIENCES
Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
PARDES BIOSCIENCES
Social Links:
Industry:
Biotechnology Life Science
Founded:
2020-01-01
Address:
Carlsbad, California, United States
Country:
United States
Website Url:
http://www.pardesbio.com
Total Employee:
1+
Status:
Active
Contact:
415-649-8758
Total Funding:
126.61 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Walden Biosciences
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
T. Rowe Price
T. Rowe Price investment in Post-IPO Equity - Pardes Biosciences
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Equity - Pardes Biosciences
GMF Capital
GMF Capital investment in Post-IPO Equity - Pardes Biosciences
Gilead Sciences
Gilead Sciences investment in Post-IPO Equity - Pardes Biosciences
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - Pardes Biosciences
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Pardes Biosciences
Foresite Capital
Foresite Capital investment in Post-IPO Equity - Pardes Biosciences
Monashee Investment Management
Monashee Investment Management investment in Post-IPO Equity - Pardes Biosciences
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-02 | Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board |
| 2021-11-30 | Pardes Biosciences Appoints New Chief Business and Strategy Officer |
Official Site Inspections
http://www.pardesbio.com Semrush global rank: 3.57 M Semrush visits lastest month: 4.07 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Pardes Biosciences"
Pardes Biosciences - Crunchbase Company Profile
Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19.See details»
Pardes Biosciences - Overview, News & Similar companies
Mar 2, 2022 Pardes Biosciences contact info: Phone number: (415) 649-8758 Website: www.pardesbio.com What does Pardes Biosciences do? Founded in 2020, Pardes …See details»
Pardes Biosciences Company Profile | Management and ... - Datanyze
Www.pardesbio.com Pardes Biosciences Profile and History Founded in 2020, Pardes Biosciences is a clinical-stage biopharmaceutical company focused on discovering, developing …See details»
Pardes Biosciences LLC - Company Profile and News
Company profile page for Pardes Biosciences LLC including stock price, company news, executives, board members, and contact informationSee details»
Pardes Biosciences Company Profile 2024: Valuation, Investors ...
Information on acquisition, funding, cap tables, investors, and executives for Pardes Biosciences. Use the PitchBook Platform to explore the full profile.See details»
Pardes Biosciences, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Pardes Biosciences, Inc. of Carlsbad, CA. Get the latest business insights from Dun & Bradstreet.See details»
Pardes Biosciences Enters into Agreement to be Acquired by
Jul 17, 2023 The Company intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for …See details»
Pardes Biosciences - Products, Competitors, Financials, Employees ...
Headquarters Location. 2173 Salk Avenue Suite 250. Carlsbad, California, 92008, United States. 415-649-8758See details»
Pardes Biosciences Debuts as a Publicly Traded Company Focused …
Dec 27, 2021 “We founded Pardes Biosciences in early 2020 to help solve pandemic-sized problems, starting with COVID-19,” said Uri A. Lopatin, M.D., Chief Executive Officer of …See details»
Pardes Biosciences Debuts as a Publicly Traded Company
Dec 27, 2021 [email protected]. Laurence Watts Gilmartin Group (619) 916-7620 [email protected]. Stephen Jasper Gilmartin Group (858) 525-2047 …See details»
Recommended Stories - Yahoo Finance
CARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby …See details»
Pardes Biosciences: We break viruses - Y Combinator
Dec 28, 2021 We break viruses. Founded in 2020 by Uri Lopatin, Pardes Biosciences has 2 employees based in San Francisco, CA, USA.See details»
Pardes Biosciences and FS Development Corp. II Announce Merger ...
Jun 29, 2021 For more information, visit www.pardesbio.com. About FS Development Corp. II (FSII) FS Development Corp. II, sponsored by Foresite Capital, is a blank check company …See details»
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an …
CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, …See details»
Pardes Biosciences Reports Fourth Quarter and Full Year
Mar 14, 2023 Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for …See details»
Pardes Biosciences Reports Full Year 2021 Financial Results and ...
CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand …See details»
FSII and Pardes Biosciences Move Towards Merger With the Goal …
Dec 21, 2021 Pardes Investor Contacts: Laurence Watts Gilmartin Group (619) 916-7620 [email protected] Stephen Jasper Gilmartin Group (858) 525-2047 …See details»
Pardes Bioscience Announces Issuance of Its First U.S. Patent
Sep 21, 2021 The patent provides coverage for compounds that target the main protease of the SARS-CoV-2 virusCARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes …See details»
Pardes Biosciences Reports Second Quarter 2022 Financial
Aug 15, 2022 For more information, please visit www.pardesbio.com. About PBI-0451 PBI-0451 is a novel, direct-acting oral antiviral drug candidate for the treatment and prevention of SARS …See details»
Pardes Biosciences Reports Third Quarter 2022 Financial Results …
Nov 7, 2022 Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected in first quarter of 2023CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- …See details»